BioVie Inc. (BIVI)
BIVINASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.15
-0.0218 (-1.86%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $12.12m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8200 to $3.79
- Average volume
- –
- Previous close
- $1.17
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$5.29m | -$6.26m | -$5.38m | -$5.72m |
| Net income | -$5.09m | -$6.07m | -$5.27m | -$5.65m |
News
8 latest- BioVie Reports Distinct Biomarker Responses In Phase 2 Long COVID Trial; Stock Down RTTNews · 6 days ago
- BioVie Inc. Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private PlacementFintel · Nov 6, 2026
- BioVie Announces $4.74 Mln Registered Direct Offering; Shares Fall 26% RTTNews · Nov 4, 2026
- BioVie's Bezisterim Shows Positive Signals In Long COVID Patients With Greater Symptom Burden RTTNews · Oct 19, 2026
- BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down RTTNews · Sep 15, 2026
- BioVie To Present Phase 2 ADDRESS-LC Topline Data On Bezisterim's Potential In Long COVID; Today RTTNews · Sep 15, 2026
- BioVie Doses Final Patient In Phase 2 Trial For Bezisterim In Long COVID; Stock Up RTTNews · Aug 31, 2026
- After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data RTTNews · Aug 20, 2026
The company
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer's and Parkinson's disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue. In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- bioviepharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.